Canaccord Genuity Reiterates a 'Buy' on STAAR Surgical (STAA); Attractive Small-cap Growth Idea
Tweet Send to a FriendGet Alerts STAA Hot Sheet
Price: $10.36 -1.43%
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Trade STAA Now!
Canaccord Genuity reiterates a 'Buy' on STAAR Surgical (NASDAQ: STAA) price target of $14.50.
Analyst, Jason R. Mills, said, "STAAR hosted several activities leading into the ASCRS meeting, including a cocktail reception for surgeons, an analyst meeting, and in-booth presentations. We were able to get granularity on the company’s US practice development plans as well as upcoming OUS drivers, which bolster our confidence in STAA as an attractive small-cap growth idea."
"If STAA is able to achieve our estimates, the stock deserves a multiple commensurate to this rarified group, in our view. In sum, we assign a 6x EV/sales multiple to 2014E revenue of $100M, discounted back two years at 6.5%, to reach our $14.50 year-end target. We also note that the company has approximately $128M worth of net operating loss carry-forwards, which equates to approximately $3.50/share."
For an analyst ratings summary and ratings history on STAAR Surgical click here. For more ratings news on STAAR Surgical click here.
Shares of STAAR Surgical closed at $11.00 yesterday, with a 52 week range of $4.48-$11.79.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Jason R. Mills, said, "STAAR hosted several activities leading into the ASCRS meeting, including a cocktail reception for surgeons, an analyst meeting, and in-booth presentations. We were able to get granularity on the company’s US practice development plans as well as upcoming OUS drivers, which bolster our confidence in STAA as an attractive small-cap growth idea."
"If STAA is able to achieve our estimates, the stock deserves a multiple commensurate to this rarified group, in our view. In sum, we assign a 6x EV/sales multiple to 2014E revenue of $100M, discounted back two years at 6.5%, to reach our $14.50 year-end target. We also note that the company has approximately $128M worth of net operating loss carry-forwards, which equates to approximately $3.50/share."
For an analyst ratings summary and ratings history on STAAR Surgical click here. For more ratings news on STAAR Surgical click here.
Shares of STAAR Surgical closed at $11.00 yesterday, with a 52 week range of $4.48-$11.79.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Madison Square Garden (MSG) is a Stock to Own on Sport Team Value and Hidden Value of The Garden - Needham & Company
- STAAR Surgical (STAA) Approved to Market Visian ICL in Korea, Argentina
Create E-mail Alert Related Categories
Analyst Comments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
